2. Search Result
Search Result
Results for "

antimetastatic agent

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113462
    α-Carotene

    		Others Cancer
    α-Carotene, a precursor of vitamin A, is used as an anti-metastatic agent or as an adjuvant for anti-cancer agents. α-Carotene is isolated from yellow-orange and dark-green vegetables .
    α-Carotene
  • HY-111578
    BDP-13176
    1 Publications Verification

    		 Arp2/3 Complex Cancer
    BDP-13176 is a potent fascin 1 inhibitor, with a Kd of 90 nM and an IC50 of 240 nM. BDP-13176 has potential as an anti-metastatic agent .
    BDP-13176
  • HY-122714
    SK-216

    		PAI-1 Cancer
    SK-216 is a plasminogen activator inhibitor-1 (PAI-1) inhibitor that acts as an anti-metastatic agent for human osteosarcoma and inhibits lung metastasis of human osteosarcoma .
    SK-216
  • HY-103070
    PythiDC

    		MMP Inflammation/Immunology
    PythiDC is a selective collagen prolyl 4-hydroxylase (CP4H1) inhibitor with an IC50 value of 4.0 μM. PythiDC can be used as a CP4H probe and also can be used for the development of a new class of antifibrotic and antimetastatic agents .
    PythiDC
  • HY-116434
    LY 189332

    		Others Cancer
    LY 189332 is a potent antimetastatic agent. LY 189332 inhibits spontaneous lung metastasis .
    LY 189332
  • HY-162379
    Anticancer agent 200

    		Others Cancer
    Anticancer agent 200 (6d) is a potential noncovalent anticancer inhibitor and an anti-metastatic agent .
    Anticancer agent 200
  • HY-116107
    AG311

    		Necroptosis Cancer
    AG311 is an anticancer and antimetastatic agent. AG311 induces rapid necrosis in numerous cancer cell lines .
    AG311
  • HY-121076
    Berteroin

    		Bacterial Infection Inflammation/Immunology Cancer
    Berteroin, a naturally occurring Sulforaphane analog, ia an antimetastatic agent. Berteroin has anti-inflammatory, antitumor and bactericidal effects .
    Berteroin
  • HY-19118
    KP1019

    FFC14A

    		 Apoptosis Cancer
    KP1019 (FFC14A) is a Ru(III)-based anti-metastatic and cytotoxic anti-cancer agent. KP1019 induces DNA damage and apoptosis in cancer cells .
    KP1019
  • HY-149344
    Anticancer agent 133

    		Apoptosis Autophagy EGFR Cancer
    Anticancer agent 133 (compound Rh2) is an anti-cancer agent with cytotoxic and antimetastatic activities. Anticancer agent 133 induces cell cycle arrest, apoptosis, and autophagy. Anticancer agent 133 also inhibits cell metastasis via suppression of EGFR expression mediated by FAK-regulated integrin β1 .
    Anticancer agent 133
  • HY-100415
    UKI-1

    WX-UK1; UKI-1C

    		 PAI-1 Ser/Thr Protease Cancer
    UKI-1 (WX-UK1) is a potent urokinase-type plasminogen activator (uPA) inhibitor with a Ki of 0.41 μM. UKI-1 is also a low molecular weight serine protease inhibitor. UKI-1 is a potent antimetastatic agent and inhibits the invasive capacity of carcinoma cells .
    UKI-1
  • HY-147522
    ADG-2e

    		Bacterial Antibiotic Infection Cancer
    ADG-2e is a potent antibacterial agent with MICs of 16, 4, 2, and 2 μg/mL for E. coli [KCTC 1682], P. aeruginosa [KCTC 1637], B.subtilis [KCTC 3068], and S. aureus [KCTC 1621], respectively. ADG-2e shows anti-metastatic activity against breast cancer cells .
    ADG-2e
  • HY-175276
    JNK-IN-24

    		JNK MMP Cancer
    JNK-IN-24, a JNK inhibitor, is an anti-metastatic cancer agent. JNK-IN-24 downregulates JNK and MMP1 expression in Scrib knockdown induced cancer tissues. JNK-IN-24 promotes recovery from tumorous wing disc phenotype of Scrib RNAi. JNK-IN-24 can be used for the study in various epithelial cell-derived cancers .
    JNK-IN-24
  • HY-130326
    RAPTA-C

    Ru(η6-p-cymene)Cl2(pta)

    		 Apoptosis Caspase Cardiovascular Disease Cancer
    RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model .
    RAPTA-C

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: